Apeiron Synthesis
Grazyna Szymanska Schellenberg serves as the President of Apeiron Synthesis, Inc. since January 2014, providing strategic solutions in olefin metathesis catalysis for the pharmaceutical, agrochemical, and flavor and fragrance industries. Szymanska Schellenberg is an active member of the New England Women in Science Executives Club (NEWISE) since December 2014 and Mass Medical Angels (MA2) since April 2011, both organizations promoting leadership and investment in life sciences and healthcare. Previously, Szymanska Schellenberg held leadership positions including Managing Director at Golden Seeds, focusing on women-centric business startups, and VP of Corporate Development at ViThera Pharmaceuticals, dedicated to innovative treatments for inflammatory bowel disease. With earlier roles at TEI Biosciences, Tolerx, Curis, and Creative BioMolecules, as well as research experience at Boston College, Szymanska Schellenberg holds a Ph.D. in Biochemistry from the Polish Academy of Sciences and an MS in Molecular Biology from the University of Warsaw.
This person is not in any teams
This person is not in any offices
Apeiron Synthesis
The mission of Apeiron Synthesis is to fully realize the potential of olefin metathesis in synthetic chemistry, with efficient and cost-effective solutions for R&D and commercial manufacturing processes – solutions that can benefit a wide range of industries, including agrichemicals, fine chemicals, flavor and fragrances, polymers and Pharma/Biopharma. Catalytic olefin metathesis technology offers chemists remarkable efficiency over traditional methods for building complex molecules - fewer synthetic steps and byproducts, reduced waste, and higher reaction concentrations - significantly lowering costs. Apeiron has developed a growing portfolio of over twenty high performance metathesis catalysts, available in milligram to multi-kilogram quantities, designed to accommodate a wide range of applications. With an uncompromising commitment to the design and use of robust new catalysts, our team of specialists is available to help customers transform their chemistry with metathesis technology. Olefin metathesis was discovered in the 1950’s as “olefin disproportionation”, with primarily industrial applications using harsh conditions. The first generations of homogeneous metathesis catalyses enabled transformations using relatively mild reaction conditions, with the potential to revolutionize the way chemists synthesize organic molecules – recognized as such with the 2005 Nobel Prize for Chemistry awarded to pioneers in the field. Apeiron is leading the way to diverse new applications to transform catalytic olefin metathesis from a technology with high potential to an important part of every chemist’s toolkit.